NEMYSIS LIMITED

Nemysis Limited is a speciality pharmaceutical company founded by industry experts and entrepreneurs with a proven record of bringing healthcare products to market. The firm is dedicated to tackling worldwide nutritional deficiencies while safeguarding the patient's microbiome, thereby minimising the gastrointestinal side-effects that often accompany conventional supplements.

The company's pipeline centres on innovative, microbiome-friendly therapies. Its flagship iron supplement, Iron Hydroxide Adipate Tartrate (IHAT), uses a nano-particulate, organic-acid-doped ferritin design that mimics natural iron absorption, reducing the typical GI irritation of standard iron products. In the realm of gluten-related disorders, Nemysis is developing the endoprotease E40, which breaks down immunogenic gluten peptides to ease symptoms for those with coeliac disease or non-coeliac gluten sensitivity. A pioneering delivery matrix is also under development to protect enzymes and other actives as they transit the stomach, ensuring release at the intended site in the small intestine.

Through collaborations with leading academic institutions and a multidisciplinary team, Nemysis aims to deliver therapeutic solutions that improve patients' everyday lives while preserving a healthy gut microbiota. The company welcomes product-innovation partnerships and investment opportunities to accelerate its mission.